Process engineers that develop monoclonal antibody (mAb) purification processes are forced to take on an array of challenges such as accommodating increased titers in upstream bioprocessing.
![](https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/icons/success.png)
Subscribed
You have successfully submitted your enquiry. Someone from our company will respond ASAP